Carteololum [Inn-Latin] en es it fr

Carteololum [Inn-Latin] Brand names, Carteololum [Inn-Latin] Analogs

Carteololum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Carteololum [Inn-Latin] Chemical_Formula


Carteololum [Inn-Latin] RX_link

Carteololum [Inn-Latin] fda sheet

Carteololum [Inn-Latin] msds (material safety sheet)

Carteololum [Inn-Latin] Synthesis Reference

No information avaliable

Carteololum [Inn-Latin] Molecular Weight

292.373 g/mol

Carteololum [Inn-Latin] Melting Point

No information avaliable

Carteololum [Inn-Latin] H2O Solubility

No information avaliable

Carteololum [Inn-Latin] State


Carteololum [Inn-Latin] LogP


Carteololum [Inn-Latin] Dosage Forms

Ophthalmic Solution (1%)

Carteololum [Inn-Latin] Indication

For the treatment of intraocular hypertension and chronic open-angle glaucoma

Carteololum [Inn-Latin] Pharmacology

Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Carteololum [Inn-Latin] Absorption

No information avaliable

Carteololum [Inn-Latin] side effects and Toxicity

The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.

Carteololum [Inn-Latin] Patient Information

No information avaliable

Carteololum [Inn-Latin] Organisms Affected

Humans and other mammals